ION Breast Cancer Clinical Pathways - ION Solutions
ION Breast Cancer Clinical Pathways - ION Solutions
ION Breast Cancer Clinical Pathways - ION Solutions
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Taxotere (Docetaxel) EP=Low; FN=10%-20%Docetaxel 40mg/m 2 D1, D8, D15, D22 (or q3wk equivalent)q 42 Day Cycle>> Semin Oncol 26:1-6, 1999>> Semin Oncol 24(Suppl 13):S11-18, 1997Abraxane (Paclitaxel Albumin-Bound) EP=Low; FN> J Clin Oncol 23:7794-7803, 2005>> J Clin Oncol 25(June 20 suppl):Abstract 1032, 2007Xeloda (Capecitabine)Capecitabine 1000-1250mg/m 2 PO BID D1-14q 21 Day Cycle>> J Clin Oncol 23:2155-2161, 2005 Epub 2005 Feb 14Gemzar (Gemcitabine) EP=Low; FN> Oncology (WillistonPark) 15(Suppl 3):11-4, 2001Navelbine (Vinorelbine) EP=Minimal; FN> <strong>Cancer</strong> 92:2267-2272, 2001Halaven (Eribulin Mesylate) EP=Low; FN> FDA LabelIxempra (Ixabepilone) EP=Low; FN> J Clin Oncol 25:3407-3414, 2007Taxotere (Docetaxel) Xeloda (Capecitabine) EP=Low; FN˃20%Docetaxel 75mg/m 2 D1Capecitabine 950mg/m 2 PO BID D1-14q 21 Day Cycle>> J Clin Oncol 20:2812-2823, 2002Gemzar (Gemcitabine) Taxol (Paclitaxel) EP=Low; FN=10%-20%Gemcitabine 1250mg/m 2 D1, D8Paclitaxel 175mg/m 2 D1q 21 Day Cycle>> J Clin Oncol 22 No 14S:510, 2004Page 10 of 39© 2013 by <strong>ION</strong> <strong>Solutions</strong>. All rights reserved
Change language